A detailed history of Ameriprise Financial Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 271,638 shares of RGNX stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
271,638
Previous 274,802 1.15%
Holding current value
$2.16 Million
Previous $3.22 Million 11.38%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.49 - $14.39 $33,190 - $45,529
-3,164 Reduced 1.15%
271,638 $2.85 Million
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $47,893 - $89,586
4,161 Added 1.54%
274,802 $3.22 Million
Q1 2024

May 15, 2024

SELL
$12.17 - $24.61 $1.29 Million - $2.61 Million
-106,087 Reduced 28.16%
270,641 $5.7 Million
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $1.51 Million - $2.44 Million
117,060 Added 45.08%
376,728 $6.76 Million
Q3 2023

Nov 14, 2023

SELL
$16.46 - $19.99 $97,146 - $117,980
-5,902 Reduced 2.22%
259,668 $4.27 Million
Q2 2023

Aug 14, 2023

SELL
$17.23 - $21.71 $481,371 - $606,533
-27,938 Reduced 9.52%
265,570 $5.31 Million
Q1 2023

May 15, 2023

BUY
$18.08 - $24.55 $1.35 Million - $1.83 Million
74,523 Added 34.03%
293,508 $5.55 Million
Q4 2022

Feb 14, 2023

SELL
$20.4 - $24.73 $130,315 - $157,975
-6,388 Reduced 2.83%
218,985 $4.97 Million
Q3 2022

Nov 14, 2022

SELL
$22.29 - $35.04 $175,756 - $276,290
-7,885 Reduced 3.38%
225,373 $5.96 Million
Q2 2022

Aug 15, 2022

SELL
$19.35 - $35.04 $53,096 - $96,149
-2,744 Reduced 1.16%
233,258 $5.76 Million
Q1 2022

May 16, 2022

BUY
$24.62 - $34.31 $7,558 - $10,533
307 Added 0.13%
236,002 $7.83 Million
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $452,578 - $603,837
14,991 Added 6.79%
235,695 $7.71 Million
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $506,893 - $795,974
17,425 Added 8.57%
220,704 $9.25 Million
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $84,947 - $105,936
-2,617 Reduced 1.27%
203,279 $7.9 Million
Q1 2021

May 17, 2021

BUY
$33.61 - $49.95 $871,339 - $1.29 Million
25,925 Added 14.41%
205,896 $7.02 Million
Q4 2020

Feb 12, 2021

SELL
$26.52 - $49.35 $558,139 - $1.04 Million
-21,046 Reduced 10.47%
179,971 $8.16 Million
Q3 2020

Nov 16, 2020

SELL
$27.01 - $40.26 $829,909 - $1.24 Million
-30,726 Reduced 13.26%
201,017 $5.53 Million
Q2 2020

Aug 14, 2020

SELL
$27.75 - $43.44 $571,511 - $894,646
-20,595 Reduced 8.16%
231,743 $8.54 Million
Q1 2020

May 15, 2020

BUY
$21.5 - $54.2 $61,662 - $155,445
2,868 Added 1.15%
252,338 $8.17 Million
Q4 2019

Feb 14, 2020

BUY
$34.54 - $44.87 $28,702 - $37,286
831 Added 0.33%
249,470 $10.2 Million
Q3 2019

Nov 14, 2019

SELL
$31.84 - $50.88 $20,377 - $32,563
-640 Reduced 0.26%
248,639 $8.85 Million
Q2 2019

Aug 14, 2019

SELL
$42.0 - $59.29 $1.41 Million - $1.98 Million
-33,462 Reduced 11.83%
249,279 $12.8 Million
Q1 2019

May 15, 2019

BUY
$40.82 - $62.45 $1 Million - $1.53 Million
24,502 Added 9.49%
282,741 $16.2 Million
Q4 2018

Feb 14, 2019

BUY
$39.11 - $75.15 $1.94 Million - $3.73 Million
49,620 Added 23.78%
258,239 $10.8 Million
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $1.07 Million - $1.36 Million
16,511 Added 8.59%
208,619 $15.8 Million
Q2 2018

Aug 14, 2018

BUY
$27.2 - $74.35 $5.23 Million - $14.3 Million
192,108 New
192,108 $13.8 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $344M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.